FATE THERAPEUTICS INC Payments of Stock Issuance Costs
FATE THERAPEUTICS INC (FATE) reported Payments of Stock Issuance Costs of $5.50 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-11-12
- FATE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2024-03-31 was $5.50M.
- FATE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2018-06-30 was $19.00K.
- FATE THERAPEUTICS INC payments of stock issuance costs for the quarter ending 2018-03-31 was $251.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 3 month as first filed | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 77 month |
|---|---|---|---|---|---|
| 2024-03-31 | $5.50M 10-Q · filed 2024-11-12 | $5.30M 10-Q · filed 2024-05-09 | |||
| 2018-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $270.00K 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $251.00K 10-Q · filed 2019-05-07 | ||||
| 2013-09-30 | $1.38M 10-Q · filed 2013-11-13 | $1.38M 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |